$25.33
1.67% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US81734D1046
Symbol
SEPN
Sector
Industry

Septerna Stock price

$25.33
+0.55 2.22% 1M
+7.33 40.72% 6M
+7.33 40.72% YTD
+7.33 40.72% 1Y
+7.33 40.72% 3Y
+7.33 40.72% 5Y
+7.33 40.72% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.43 1.67%
ISIN
US81734D1046
Symbol
SEPN
Sector
Industry

Key metrics

Market capitalization $1.12b
P/B ratio (TTM) P/B ratio negative
Cash position $130.53m
P/E forward negative
P/S forward 1,571.39

Is Septerna a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Septerna Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Septerna forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Septerna forecast:

Buy
100%

Financial data from Septerna

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.18 0.18
500% 500%
100%
- Direct Costs 0.36 0.36
57% 57%
200%
-0.19 -0.19
5% 5%
-106%
- Selling and Administrative Expenses 4.17 4.17
79% 79%
2,317%
- Research and Development Expense 18 18
92% 92%
9,906%
-22 -22
88% 88%
-12,328%
- Depreciation and Amortization 0.36 0.36
57% 57%
200%
EBIT (Operating Income) EBIT -23 -23
87% 87%
-12,528%
Net Profit -21 -21
87% 87%
-11,400%

In millions USD.

Don't miss a Thing! We will send you all news about Septerna directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Septerna Stock News

Neutral
GlobeNewsWire
11 days ago
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 3:45 p.m. PT in San Francisco.

Company Profile

Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.

Head office United States
CEO Jeffrey Finer
Website www.septerna.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today